CAC
BIOT

Cowen and Company’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Cowen and Company’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$1.49M – 819
2022
Q2 		$1.49M Buy
+150,000
New +$1.47M 0.14% 76

Other funds holding BIOT

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cowen and Company's BIOT Position: Q3 2022 in Review

Cowen and Company sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2022, closing a stake of 150,000 shares — an estimated $1.49M sold.

Cowen and Company first reported a position in BIOT in Q2 2022 and held it in 1 quarter. The position peaked at $1.49M in Q2 2022. 69 funds tracked by Wall St. Rank hold BIOT as of Q3 2022.

  • Cowen and Company reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 150,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2022, an estimated $1.49M.
  • Cowen and Company first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2022 and held it in 1 quarter.
  • Cowen and Company's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.49M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.